Treatment of AL amyloidosis with high dose therapy and autologous stem cell transplantation.
Dimopoulos
Meletios A
MA
Department of Clinical Therapeutics, University of Athens, School of Medicine, Athens, Greece. mdimop@med.uoa.gr
D000368:Aged; D000686:Amyloidosis / Q000628:therapy*; D001854:Bone Marrow Cells / Q000473:pathology; D002986:Clinical Trials as Topic; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000737:chemistry*; D007075:Immunoglobulin M / Q000737:chemistry / Q000276:immunology*; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D033581:Stem Cell Transplantation / Q000379:methods*; D014182:Transplantation, Autologous / Q000379:methods*; D016896:Treatment Outcome
D007147:Immunoglobulin Light Chains; D007075:Immunoglobulin M; D008558:Melphalan